Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSEmpagliflozin-d4 is intended for use as an internal standard for the quantification of empagliflozin (Item No. 17375) by GC- or LC-MS. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 3.1 nM for the human transporter).1 It is selective for SGLT2 over SGLT1, -4, -5, and -6 (IC50s = 8.3, 11, 1.1, and 2 µM, respectively). Dietary administration of empagliflozin (0.03% for 10 weeks) reduces non-fasting blood glucose levels, as well as aortic superoxide levels and cardiac interstitial fibrosis, in db/db mice.2 It also decreases the severity of glomerulosclerosis, as well as reduces the escape latency in the Morris water maze, in the same model. Formulations containing empagliflozin have been used in the treatment of type 2 diabetes.
WARNING This product is not for human or veterinary use.
1. Empagliflozin, a novel selective sodium glucose contransporter-
2. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc. Diabetol. 13, 148 (2014).